deoxycytidine has been researched along with Neuroendocrine Tumors in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (31.25) | 29.6817 |
| 2010's | 22 (68.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Endoh, T; Ikeda, K; Iwata, N; Minami, T; Sasano, H; Sugawara, N; Yoshida, Y | 1 |
| Costa, FP; Gumz, B; Pasche, B | 1 |
| Ng, J; Ove, R; Russo, S; Saif, MW | 1 |
| Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW | 1 |
| Garcon, MC; Kaley, K; Rodriguez, T; Saif, MW | 1 |
| Armstrong, G; Caplin, ME; Corrie, PG; Cunningham, D; Hardy, R; Lao-Sirieix, SH; Luong, TV; Meyer, T; Navalkissoor, S; Qian, W; Reed, N; Shaw, A; Talbot, DC; Valle, JW | 1 |
| Saif, MW; Tejani, MA | 1 |
| Amoroso, V; Berruti, A; Biasco, G; Birocco, N; Bodei, L; Brizzi, MP; D'Avolio, A; Dogliotti, L; Fazio, N; Ferrero, A; Nobili, E; Papotti, M; Priola, AM; Torta, M; Tozzi, L; Volante, M | 1 |
| Claringbold, PG; Kesavan, M; Turner, JH | 1 |
| Abbasi, S; Albaba, H; Kashashna, A | 1 |
| Baudin, E; Bengrine-Lefevre, L; Cadiot, G; Dominguez-Tinajero, S; Dromain, C; Ducreux, M; Farace, F; Kurtz, JE; Mitry, E; Rougier, P; Ruszniewski, P; Walter, T | 1 |
| Dussol, AS; Forestier, J; Hervieu, V; Joly, MO; Lombard-Bohas, C; Scoazec, JY; Vercherat, C; Walter, T | 1 |
| Bajor, J; Balázs, A; Czakó, L; Czimmer, J; Farkas, G; Gódi, S; Halász, A; Hegyi, P; Izbéki, F; Kahán, Z; Kelemen, D; Kui, B; Lakatos, G; Leindler, L; Papp, R; Pár, G; Szabó, I; Szentesi, A; Szentkereszty, Z; Szepes, Z; Szmola, R; Szücs, Á; Takács, T; Vincze, Á | 1 |
| Abou-Alfa, GK; Blumgart, LH; Capanu, M; D'Angelica, M; Dematteo, RP; Duffy, A; Fong, Y; Huitzil, D; Jarnagin, W; O'Reilly, EM | 1 |
| Ardisson, P; Bohas, CL; Cassier, PA; Chayvialle, JA; Eymard, B; Hervieu, V; Paillet, C; Perol, M; Scoazec, JY; Walter, T | 1 |
| Gruber, T; Hammerstingl, R; Naguib, NN; Nour-Eldin, NE; Vogl, TJ | 1 |
| Hicks, RJ; Hubble, D; Johnson, V; Kong, G; Michael, M; Ramdave, S | 1 |
| Eriksson, B | 1 |
| Brayshaw, PA; Claringbold, PG; Price, RA; Turner, JH | 1 |
| Davies, JM; Farrugia, D; Hayward, N; Kirichek, O; Medley, L; Morel, AN; Reed, N; Talbot, DC; Thakker, RV | 1 |
| Broadwater, G; Clough, RW; Czito, BG; Guy, CD; Papalezova, KT; Papavassiliou, P; Tyler, DS; White, RR; Willett, CG; Zagar, TM | 1 |
| Allen, JN; Arvold, ND; Blaszkowsky, LS; Clark, JW; Deshpande, V; Fernandez-del Castillo, C; Ferrone, CR; Hong, TS; Kwak, EL; Niemierko, A; Ryan, DP; Wadlow, RC; Warshaw, AL; Willett, CG; Zhu, AX | 1 |
| Claringbold, PG; Price, RA; Turner, JH | 1 |
| Centeno, B; Kvols, L; Morse, B; Saranga-Perry, V; Strosberg, J | 1 |
| Allendorf, J; Chabot, JA; Dinnen, RD; Fine, RL; Gulati, AP; Krantz, BA; Lee, JA; Mao, Y; Moss, RA; Mowatt, KB; Schreibman, S; Schrope, B; Sherman, WH; Stevens, PD; Tsushima, DA | 1 |
| Clark, JW; Enzinger, PC; Fuchs, CS; Kim, H; Kulke, MH; Lynch, TJ; Michelini, A; Morgan, JA; Vincitore, M | 1 |
| Chin, S; Feld, R; Haider, M; Hu, H; Knox, J; Krzyzanowska, MK; Oza, AM; Siu, LL; Tsao, MS | 1 |
| Arias de la Vega, F; Gómez Dorronsoro, ML; Jiménez, FJ | 1 |
| Bajetta, E; Bajetta, R; Bichisao, E; Catena, L; De Dosso, S; Ferrari, L; Formisano, B; Martinetti, A; Platania, M; Procopio, G; Verzoni, E | 1 |
| Hayashi, H; Igarashi, H; Ito, T; Kawabe, K; Kodama, M; Sakai, H; Takayanagi, R; Yoshinaga, M | 1 |
| Ammann, M; Duquesne, A; Fürstenberger, G; Schmid, P; Senn, HJ | 1 |
| de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M | 1 |
2 review(s) available for deoxycytidine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Proliferation; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Intestinal Neoplasms; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Prognosis; Stomach Neoplasms; Streptozocin; Temozolomide | 2012 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome | 2010 |
9 trial(s) available for deoxycytidine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Quality of Life; Streptozocin; Surveys and Questionnaires; Treatment Outcome | 2014 |
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Topics: Administration, Metronomic; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Treatment Outcome | 2014 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2014 |
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neuroendocrine Tumors; Treatment Outcome | 2014 |
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Deoxycytidine; Disease Progression; Endocrine Gland Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pilot Projects; Radiometry; Salvage Therapy; Treatment Outcome | 2011 |
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors | 2011 |
Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Temozolomide; Treatment Outcome | 2012 |
A Phase II trial of gemcitabine for metastatic neuroendocrine tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neuroendocrine Tumors; Prognosis; Survival Rate; Treatment Outcome | 2004 |
Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumours.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Capecitabine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Lactones; Middle Aged; Neuroendocrine Tumors; Sulfones | 2006 |
21 other study(ies) available for deoxycytidine and Neuroendocrine Tumors
| Article | Year |
|---|---|
[A case of pancreatic neuroendocrine tumor with excessively-advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long-acting somatostatin analogue octreotide].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2013 |
Radiotherapy in the management of pancreatic neuroendocrine tumors (PNET): experience at three institutions.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant | 2013 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Remission Induction; Retrospective Studies; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2013 |
Gemcitabine as salvage treatment in patients with poorly differentiated pancreatic neuroendocrine tumors: a case series.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Differentiation; Deoxycytidine; Drug Evaluation; Fatal Outcome; Female; Gemcitabine; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Salvage Therapy; Treatment Outcome | 2014 |
Pancreatic neuroendocrine tumors: does chemotherapy work?
Topics: Algorithms; Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Cell Differentiation; Dacarbazine; Deoxycytidine; Developing Countries; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Jordan; Male; Middle Aged; Neuroendocrine Tumors; Remission Induction; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2014 |
Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2015 |
Pancreatic Cancer: Multicenter Prospective Data Collection and Analysis by the Hungarian Pancreatic Study Group.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Humans; Hungary; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neuroendocrine Tumors; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Pancreatitis, Chronic; Prognosis; Proportional Hazards Models; Prospective Studies; Registries; Risk Factors; Smoking; Stents; Young Adult | 2016 |
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Cholecystectomy, Laparoscopic; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Incidental Findings; Male; Middle Aged; Neoplasm, Residual; Neuroendocrine Tumors; Radiotherapy, Adjuvant; Retrospective Studies; Sarcoma; Survival Analysis | 2008 |
Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Evaluation; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Retreatment; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Deoxycytidine; Female; Gemcitabine; Hemostatics; Humans; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neuroendocrine Tumors; Retrospective Studies; Treatment Outcome | 2009 |
177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hematologic Tests; Humans; Kidney; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Prodrugs; Radiation-Sensitizing Agents; Receptors, Peptide; Retrospective Studies; Survival Analysis; Time Factors; Young Adult | 2010 |
Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrimidines; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure | 2012 |
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Sex Factors; Tumor Burden | 2012 |
Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thymus Neoplasms; Treatment Outcome | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2013 |
Subcutaneous metastasis as the first manifestation of a solid-pseudopapillary tumor of the pancreas.
Topics: Adenocarcinoma, Clear Cell; Aged; Antimetabolites, Antineoplastic; Arm; Biomarkers; Biomarkers, Tumor; Deoxycytidine; Diagnostic Errors; Female; Gemcitabine; Humans; Keratins; Neoplasm Proteins; Neprilysin; Neuroendocrine Tumors; Pancreatic Neoplasms; Phosphopyruvate Hydratase; Soft Tissue Neoplasms; Subcutaneous Tissue; Vimentin | 2006 |
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chromogranin A; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Analysis | 2007 |
Successful management of multiple liver metastases from pancreatic neuroendocrine tumor by hepatic arterial administration of cisplatin powder.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Drug Carriers; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Iodized Oil; Liver Neoplasms; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pancreaticoduodenectomy; Powders; Remission Induction | 2007 |
Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromogranin A; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2008 |
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Creatinine; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, Intravenous; Leukocyte Count; Male; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Platelet Count; Radioisotopes; Receptors, Somatostatin | 2008 |